Strategy for COVID-19 vaccination for patients with tuberculosis during the COVID-19 pandemic

WANG Yuan-zhou; JIA Si-yue; ZHU Feng-cai; LI Jing-xin

doi:10.16462/j.cnki.zhjbkz.2022.11.018

Volume 26 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2022 > 26(11): 1344-1348

WANG Yuan-zhou, JIA Si-yue, ZHU Feng-cai, LI Jing-xin. Strategy for COVID-19 vaccination for patients with tuberculosis during the COVID-19 pandemic[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(11): 1344-1348. doi: 10.16462/j.cnki.zhjbkz.2022.11.018

Citation:

WANG Yuan-zhou, JIA Si-yue, ZHU Feng-cai, LI Jing-xin. Strategy for COVID-19 vaccination for patients with tuberculosis during the COVID-19 pandemic[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2022, 26(11): 1344-1348. doi: 10.16462/j.cnki.zhjbkz.2022.11.018

Citation:

PDF( 796 KB)

Strategy for COVID-19 vaccination for patients with tuberculosis during the COVID-19 pandemic

doi: 10.16462/j.cnki.zhjbkz.2022.11.018

1.
School of Public Health, Nanjing Medical University, Nanjing 211166, China
2.
Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China

Funds:

National Natural Science Foundation of China 82173584

More Information

Corresponding author: LI Jing-xin, E-mail: jingxin42102209@126.com
Received Date: 2022-04-11
Rev Recd Date: 2022-07-03

Available Online: 2022-12-21

Publish Date: 2022-11-10

Abstract

Abstract

The pandemic of COVID-19 is still rampaging all over the world, so it is urgent to popularize vaccination. Meanwhile, pulmonary tuberculosis is one of the chronic infectious diseases with a high incidence in China. Since these diseases all occur in lung tissue, patients with TB and COVID-19 co-infection show more serious conditions and poorer treatment effects. However, we have limited knowledge about the protective efficacy, immunogenicity and safety of COVID-19 vaccine in patients with TB at present, with a lack of corresponding evidence-based medicine as well. Therefore, this paper reviews the pathogenesis and epidemiology of TB, discusses the immune status of patients with TB and summarizes the existing proposals for vaccination of patients with TB at home and abroad. Furthermore, we analyze the existing clinical trials in TB patients and other special populations, and finally discuss the strategy of vaccination for patients with TB during the COVID-19 pandemic and the necessity of clinical research on COVID-19 vaccines with target population of TB patients.
- SARS-CoV-2,
- COVID-19,
- Pulmonary tuberculosis,
- Vaccination,
- Inactivated vaccine,
- Clinical trial

FullText(HTML)

References(38)

References

[1]	Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges[J]. Nat Rev Immunol, 2021, 21(4): 195-197. DOI: 10.1038/s41577-021-00526-x.
[2]	WHO. WHO Coronavirus (COVID-19) dashboard[EB/OL]. (2022-02-21)[2022-03-09]. https://covid19.who.int/.
[3]	Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines[J]. JAMA, 2021, 325(13): 1318-1320. DOI: 10.1001/jama.2021.3199.
[4]	Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey[J]. Lancet, 2021, 398(10296): 213-222. DOI: 10.1016/S0140-6736(21)01429-X.
[5]	Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile[J]. N Engl J Med, 2021, 385(10): 875-884. DOI: 10.1056/NEJMoa2107715.
[6]	Fadlyana E, Rusmil K, Tarigan R, et al. A phase Ⅲ, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia[J]. Vaccine, 2021, 39(44): 6520-6528. DOI: 10.1016/j.vaccine.2021.09.052.
[7]	WHO. Global tuberculosis report 2021[EB/OL]. (2021-10-14) [2022-03-09]. https://www.who.int/publications/i/item/9789240037021.
[8]	Tadolini M, Codecasa LR, García-García JM, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases[J]. Eur Respir J, 2020, 56(1): 2001398. DOI: 10.1183/13993003.01398-2020.
[9]	Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection[J]. Clin Microbiol Rev, 2018, 31(4): e00021-e00018. DOI: 10.1128/CMR.00021-18.
[10]	Shah M, Dorman SE. Latent tuberculosis infection[J]. N Engl J Med, 2021, 385(24): 2271-2280. DOI: 10.1056/NEJMcp2108501.
[11]	Furin J, Cox H, Pai M. Tuberculosis[J]. Lancet, 2019, 393(10181): 1642-1656. DOI: 10.1016/S0140-6736(19)30308-3.
[12]	McQuaid CF, McCreesh N, Read JM, et al. The potential impact of COVID-19-related disruption on tuberculosis burden[J]. Eur Respir J, 2020, 56(2): 2001718. DOI: 10.1183/13993003.01718-2020.
[13]	Silva S, Arinaminpathy N, Atun R, et al. Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis[J]. Lancet Glob Health, 2021, 9(10): e1372-e1379. DOI: 10.1016/S2214-109X(21)00299-0.
[14]	Ravimohan S, Kornfeld H, Weissman D, et al. Tuberculosis and lung damage: from epidemiology to pathophysiology[J]. Eur Respir Rev, 2018, 27(147)170077. DOI: 10.1183/16000617.0077-2017.
[15]	Goossens SN, Sampson SL, Van Rie A. Mechanisms of drug-Induced tolerance in Mycobacterium tuberculosis[J]. Clin Microbiol Rev, 2020, 34(1): e00141-e00161. DOI: 10.1128/CMR.00141-20.
[16]	Xu W, Snell LM, Guo M, et al. Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection[J]. Immunity, 2021, 54(3): 526-541. DOI: 10.1016/j.immuni.2021.01.003.
[17]	McCaffrey EF, Donato M, Keren L, et al. The immunoregulatory landscape of human tuberculosis granulomas[J]. Nat Immunol, 2022, 23(2): 318-329. DOI: 10.1038/s41590-021-01121-x.
[18]	Sharan R, Bucşan AN, Ganatra S, et al. Chronic immune activation in TB/HIV co-infection: (trends in microbiology 28, 619-632; 2020)[J]. Trends Microbiol, 2020, 28(8): 699. DOI: 10.1016/j.tim.2020.05.006.
[19]	Seto S, Tsujimura K, Koide Y. Coronin-1a inhibits autophagosome formation around Mycobacterium tuberculosis-containing phagosomes and assists mycobacterial survival in macrophages[J]. Cell Microbiol, 2012, 14(5): 710-727. DOI: 10.1111/j.1462-5822.2012.01754.x.
[20]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity[J]. Nature, 2020, 577(7792): 682-688. DOI: 10.1038/s41586-019-1915-7.
[21]	Khan N, Downey J, Sanz J, et al. M. tuberculosis reprograms hematopoietic stem cells to limit myelopoiesis and impair trained immunity[J]. Cell, 2020, 183(3): 752-770. DOI: 10.1016/j.cell.2020.09.062.
[22]	Roy Chowdhury R, Vallania F, Yang QT, et al. A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes[J]. Nature, 2018, 560(7720): 644-648. DOI: 10.1038/s41586-018-0439-x.
[23]	Joosten SA, van Meijgaarden KE, del Nonno F, et al. Patients with tuberculosis have a dysfunctional circulating b-cell compartment, which normalizes following successful treatment[J]. PLoS Pathog, 2016, 12(6): e1005687. DOI: 10.1371/journal.ppat.1005687.
[24]	CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States[EB/OL]. (2022-03-07)[2022-03-29]. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#special-populations.
[25]	国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[J]. 中国病毒病杂志, 2021, 11(3): 161-162. DOI: 10.16505/j.2095-0136.2021.0018. Bureau of Disease Control and Prevention, National Health Commission of the People's Republic of China. Guidelines of vaccination for COVID-19 vaccines in China (First edition)[J]. Chin J Viral Dis, 2021, 11(3): 161-162. DOI: 10.16505/j.2095-0136.2021.0018.
[26]	曹玮. 慢性肝病、结核病和风湿免疫病患者接种新冠疫苗的专家建议[J]. 中华医学信息导报, 2021, 36(15): 6. DOI: 10.3760/cma.j.issn.1000-8039.2021.15.107. Cao W. Expert recommendation on severe acute respiratory syndrome coronavirus 2 vaccination in patients with chronic liver diseases, tuberculosis or rheumatoid diseases[J]. Chin Med News, 2021, 36(15): 6. DOI: 10.3760/cma.j.issn.1000-8039.2021.15.107.
[27]	殷荣, 钮蕴超, 缪晓辉. 《特殊人群(慢性肝病、结核病和风湿免疫病患者)新型冠状病毒疫苗接种专家建议》解读[J]. 中华传染病杂志, 2021, 39(10): 588-590. DOI: 10.3760/cma.j.cn311365-20210623-00222. Yin R, Niu YC, Miu XH. Interpretation of "Expert recommendation on severe acute respiratory syndrome coronavirus 2 vaccination in patients with chronic liver diseases, tuberculosis or rheumatoid diseases"[J]. Chin J Infect Dis, 2021, 39(10): 588-590. DOI: 10.3760/cma.j.cn311365-20210623-00222.
[28]	卢水华, 夏露. 结核病患者接种新型冠状病毒疫苗的专家建议[J]. 中国防痨杂志, 2021, 43(12): 1239-1242. DOI: 10.3969/j.issn.1000-6621.2021.12.003. Lu SH, Xia L. Expert advice on anti-novel coronavirus vaccination for tuberculosis patients[J]. Chin J Antituberc, 2021, 43(12): 1239-1242. DOI: 10.3969/j.issn.1000-6621.2021.12.003.
[29]	Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2021, 80(3): 384-391. DOI: 10.1136/annrheumdis-2020-218946.
[30]	Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial[J]. Nat Med, 2021, 27(10): 1744-1751. DOI: 10.1038/s41591-021-01469-5.
[31]	Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study[J]. Ann Rheum Dis, 2021, 80(10): 1330-1338. DOI: 10.1136/annrheumdis-2021-220647.
[32]	Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort[J]. Ann Rheum Dis, 2021, 80(10): 1306-1311. DOI: 10.1136/annrheumdis-2021-220272.
[33]	Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial[J]. Lancet HIV, 2021, 8(8): e474-e485. DOI: 10.1016/S2352-3018(21)00103-X.
[34]	Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial[J]. Lancet HIV, 2021, 8(9): e568-e580. DOI: 10.1016/S2352-3018(21)00157-0.
[35]	Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors[J]. Nat Med, 2021, 27(11): 2002-2011. DOI: 10.1038/s41591-021-01542-z.
[36]	Waldhorn I, Holland R, Goshen-Lago T, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors[J]. Cancer Discov, 2021, 11(10): 2430-2435. DOI: 10.1158/2159-8290.CD-21-1072.
[37]	Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial[J]. Lancet Oncol, 2021, 22(12): 1681-1691. DOI: 10.1016/S1470-2045(21)00574-X.
[38]	Lee A, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis[J]. BMJ, 2022, 376: e068632. DOI: 10.1136/bmj-2021-068632.